Multidose formulation of ready-to-use 177Lu-PSMA-617 in a centralized radiopharmacy set-up

被引：11
|
作者：
Chakraborty, Sudipta [1 ,3 ]
Vimalnath, K. V. [1 ]
Chakravarty, Rubel [1 ,3 ]
Sarma, H. D. [2 ]
Dash, Ashutosh [1 ,3 ]
机构：
[1] Bhabha Atom Res Ctr, Radiopharmaceut Div, Bombay 400085, Maharashtra, India
[2] Bhabha Atom Res Ctr, Radiat Biol & Hlth Sci Div, Bombay 400085, Maharashtra, India
[3] Homi Bhabha Natl Inst, Bombay 400094, Maharashtra, India
来源：
APPLIED RADIATION AND ISOTOPES | 2018年 / 139卷
关键词：
Prostate cancer; PSMA-617; Lu-177; Multidose formulation; Stability; Shelf-life; RESISTANT PROSTATE-CANCER; RADIOLIGAND THERAPY; RADIONUCLIDE THERAPY;
D O I：
10.1016/j.apradiso.2018.04.033
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
Lutetium-177-labeled PSMA inhibitor has emerged as a promising modality for targeted therapy of prostate carcinoma. A protocol for regular multidose formulation of ready-to-use Lu-177-PSMA-617 has been developed based on detailed and systematic radiochemical investigations. The formulation meets the requirements of clinical use and can be shipped to nuclear medicine centres for administration up to 4 days from the date of formulation. The reported protocol would be useful toward facilitating widespread clinical utilization of (177)LuPSMA-617 in the management of prostate cancer.
引用
收藏
页码：91 / 97
页数：7
相关论文
共 18 条
  • [1] Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy
    Chakraborty, Avik
    Mitra, Arpit
    Tawate, Megha
    Sahoo, Sudip
    Lad, Sangita
    Rakshit, Sutapa
    Gaikwad, Sujay
    Basu, Sandip
    Shimpi, Hemant
    Banerjee, Sharmila
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021, 36 (08) : 682 - 692
  • [2] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [3] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [4] Formulation of clinical-scale 177Lu-PSMA-617: From laboratory to clinics
    Das, Tapas
    Guleria, Mohini
    Banerjee, Sharmila
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 836
  • [5] Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House
    Guleria, Mohini
    Amirdhanayagam, Jeyachitra
    Sarma, Haladhar D.
    Rallapeta, Ramya Priya
    Krishnamohan, V. S.
    Nimmagadda, Ajit
    Ravi, Parthasarathy
    Patri, Sailaja
    Kalawat, Tekchand
    Das, Tapas
    [J]. BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [6] SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
    Hope, Thomas A.
    Antonarakis, Emmanuel S.
    Bodei, Lisa
    Calais, Jeremie
    Iravani, Amir
    Jacene, Heather
    Koo, Phillip J.
    Morgans, Alicia K.
    Osborne, Joseph R.
    Tagawa, Scott T.
    Taplin, Mary-Ellen
    Sartor, Oliver
    Morris, Michael J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09): : 1417 - 1423
  • [7] Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists
    Nguyen, Jennifer
    Patel, Jeetvan
    Kang, Barinder
    Yu, Channing
    Sawhney, Amrita
    Fallick, Mark
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Paltanwale, Queenie
    Sun, Kainan
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
    Ahmadzadehfar, Hojjat
    Essler, Markus
    Schaefers, Michael
    Rahbar, Kambiz
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 835
  • [9] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [10] Ready-to-use 177Lu-Rituximab injection for Non-Hodgkin’s Lymphoma: Formulation and preliminary clinical study
    Mythili Kameswaran
    Usha Pandey
    Naresh Gamre
    Ajit Shinto
    Suresh Subramanian
    Haladhar Dev Sarma
    K. K. Kamleshwaran
    Ashutosh Dash
    [J]. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318 : 849 - 856
12